MakeMyTripの空売り状況は、投資家がMakeMyTripの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

MakeMyTrip (NASDAQ:MMYT) 株価情報, 空売り情報

MakeMyTrip

MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.

MakeMyTrip Ltd

WIIM

AENT

ALUR

BKNG

CVNA

New Oriental Education & Technology Group

GROV

MBLY

MMYT

RIME

SPGC

WRBY

YUMC

ZSPC

Shares of companies within the broader consumer discretionary sector are trading lower amid overall market weakness due to a rise in yields.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs cut the price target for Bright Horizons Family Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) from $162 to $142. Goldman Sachs analyst George Tong maintained a Buy rating. Bright Horizons Family Solutions shares closed at $110.83 on Thursday. <a href="https://www.benzinga.com/quote/BFAM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rodman &amp; Renshaw raised Viracta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) price target from $3.5 to $0.25. Rodman &amp; Renshaw downgraded the stock from Buy to Neutral. Viracta Therapeutics shares closed at $0.2370 on Thursday. <a href="https://www.benzinga.com/quote/VIRX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised the price target for Masimo Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) from $170 to $194. Raymond James analyst Jayson Bedford maintained an Outperform rating. Masimo shares closed at $171.02 on Thursday. <a href="https://www.benzinga.com/quote/MASI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed the price target for KinderCare Learning Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) from $41 to $35. Goldman Sachs analyst George Tong maintained a Buy rating. KinderCare Learning shares closed at $17.88 on Thursday. <a href="https://www.benzinga.com/quote/KLC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities boosted MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) price target from $119 to $130. B of A Securities analyst Sachin Salgaonkar maintained a Buy rating. MakeMyTrip shares settled at $116.21 on Thursday. <a href="https://www.benzinga.com/quote/MMYT/analyst-ratings">See how other analysts view this stock</a>. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42697989/dow-edges-higher-in-thin-holiday-trading-fear-declines-among-us-investors-but-fear-greed-index-remains-in-fear-zone">Dow Edges Higher In Thin Holiday Trading As Tesla, Apple Surge: Investor Sentiment Improves, But Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BFAM

MASI

VIRX

Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday

B of A Securities analyst Sachin Salgaonkar maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $119 to $130.

B of A Securities Maintains Buy on MakeMyTrip, Raises Price Target to $130

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Tuesday.
Shares of United Natural Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) rose sharply during Tuesday's session following better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/UNFI/earnings">raised its FY25 guidance.</a>
United Natural Foods posted adjusted earnings of 16 cents per share, compared to market estimates for a loss of 1 cent per share. The company's quarterly sales came in at $7.87 billion versus expectations of $7.61 billion.
United Natural Foods shares surged 29% to $31.82 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) shares jumped 105.6% to $15.00 after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.</li>
<li>NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) gained 35.5% to $25.10 after the company announced topline data from its Phase 3 BROADWAY trial of Obicetrapib.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) gained 21.5% to $3.8999.</li>
<li>Byrna Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) surged 16.7% to $22.09 as the company announced preliminary fiscal fourth quarter record revenues of $28.0 million.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) gained 15.1% to $5.12. Quantum Machines and Rigetti announced successful AI-powered calibration of a Quantum Computer.</li>
<li>Solaris Energy Infrastructure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) gained 15.1% to $29.65. Solaris Energy Infrastructure priced its public offering of 6.5 million Class A shares at $24.75 each for net proceeds of $156 million.</li>
<li>Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) jumped 14.7% to $111.48 after the company reported better-than-expected third-quarter financial results.</li>
<li>MoneyLion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) gained 14.7% to $88.30 after the company announced an agreement to be acquired for $82 per share in cash for a total value of approximately $1 billion.</li>
<li>Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) rose 13.5% to $61.54 r after the company unveiled &#8220;Alaska Accelerate&#8221;, a strategy to boost profitability and its global footprint. Additionally, the company issued a strong FY25 outlook and plans for nonstop routes to Tokyo and Seoul from Seattle.</li>
<li>Nebius Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>) gained 6.2% to $33.94.</li>
<li>Super Group (SGHC) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) rose 5.9% to $7.01. The company issued business update as 2024 closes.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) climbed 5.5% to $121.32 after the company inked a Business Transfer Agreement to acquire the Happay Expense Management Platform from CRED for an undisclosed amount.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) gained 4.6% to $183.45.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42412458/amazon-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday">Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Intraday Update

Movers

ABSI

BYRN

GOOGL

NAMS

NBIS

OLLI

QURE

RGTI

SGHC

UNFI

United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$360.00</td>
<td>$33.6K</td>
<td>22.5K</td>
<td>44.3K</td>
</tr>
<tr>
<td>AMZN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$195.00</td>
<td>$181.5K</td>
<td>9.4K</td>
<td>13.9K</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$108.00</td>
<td>$26.8K</td>
<td>1.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$76.8K</td>
<td>7.1K</td>
<td>1.1K</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.00</td>
<td>$106.5K</td>
<td>78</td>
<td>1.0K</td>
</tr>
<tr>
<td>GM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$55.00</td>
<td>$134.5K</td>
<td>2.3K</td>
<td>494</td>
</tr>
<tr>
<td>FL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$22.00</td>
<td>$40.8K</td>
<td>402</td>
<td>400</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$80.00</td>
<td>$33.3K</td>
<td>295</td>
<td>305</td>
</tr>
<tr>
<td>MMYT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$125.00</td>
<td>$25.3K</td>
<td>8</td>
<td>161</td>
</tr>
<tr>
<td>PTON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$10.00</td>
<td>$37.5K</td>
<td>408</td>
<td>150</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 350 contract(s) at a $360.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $96.0 per contract. There were 22567 open contracts at this strike prior to today, and today 44374 contract(s) were bought and sold. 
• Regarding AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 1261 contract(s) at a $195.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $181.5K, with a price of $144.0 per contract. There were 9445 open contracts at this strike prior to today, and today 13975 contract(s) were bought and sold. 
• Regarding PDD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on November 22, 2024. Parties traded 80 contract(s) at a $108.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $26.8K, with a price of $335.0 per contract. There were 1878 open contracts at this strike prior to today, and today 1764 contract(s) were bought and sold. 
• For MBLY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>), we notice a call option trade that happens to be bullish, expiring in 57 day(s) on January 17, 2025. This event was a transfer of 233 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $76.8K, with a price of $330.0 per contract. There were 7128 open contracts at this strike prior to today, and today 1186 contract(s) were bought and sold. 
• For XPEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), we notice a call option sweep that happens to be bearish, expiring in 120 day(s) on March 21, 2025. This event was a transfer of 500 contract(s) at a $12.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $213.0 per contract. There were 78 open contracts at this strike prior to today, and today 1086 contract(s) were bought and sold. 
• Regarding GM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), we observe a call option sweep with bearish sentiment. It expires in 120 day(s) on March 21, 2025. Parties traded 272 contract(s) at a $55.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $134.5K, with a price of $495.0 per contract. There were 2392 open contracts at this strike prior to today, and today 494 contract(s) were bought and sold. 
• Regarding FL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>), we observe a call option sweep with bearish sentiment. It expires in 15 day(s) on December 6, 2024. Parties traded 160 contract(s) at a $22.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $40.8K, with a price of $255.0 per contract. There were 402 open contracts at this strike prior to today, and today 400 contract(s) were bought and sold. 
• For BABA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), we notice a call option trade that happens to be bullish, expiring in 147 day(s) on April 17, 2025. This event was a transfer of 30 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $33.3K, with a price of $1110.0 per contract. There were 295 open contracts at this strike prior to today, and today 305 contract(s) were bought and sold. 
• Regarding MMYT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>), we observe a call option sweep with bullish sentiment. It expires in 92 day(s) on February 21, 2025. Parties traded 46 contract(s) at a $125.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $25.3K, with a price of $550.0 per contract. There were 8 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• For PTON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>), we notice a put option trade that happens to be bearish, expiring in 147 day(s) on April 17, 2025. This event was a transfer of 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $250.0 per contract. There were 408 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMZN

BABA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PTON

TSLA

XPEV

10 Consumer Discretionary Stocks With Whale Alerts In Today's Session

MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) shares are trading higher premarket on Monday after the company inked a Business Transfer Agreement to acquire the Happay Expense Management Platform from CRED <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42031223/makemytrip-to-acquire-happay-expense-management-platform-from-cred" rel="noreferrer noopener">for an undisclosed amount</a>.
This acquisition strengthens MakeMyTrip&#8217;s position as a comprehensive solution provider for corporate travel and expense management.
The transaction is expected to close within 90 days, pending closing conditions.
Happay&#8217;s team will continue supporting its current clients and collaborate closely with MakeMyTrip&#8217;s corporate travel services team.
Rajesh Magow, Co-Founder and Group CEO, MakeMyTrip, added,&nbsp;&#8220;The acquisition of Happay&#8217;s brand and expense management platform is a natural next step in our strategy to lead this space. By integrating Happay&#8217;s expertise, which spans over 900 corporate clients, MakeMyTrip is set to redefine the benchmarks once again in corporate travel and expense management in India.&#8221;
Kunal Shah, Founder, CRED, said, &#8220;Our focus at CRED is on developing products that enable financial progress. By enabling each vertical to play to its strengths, we&#8217;re positioning both teams &#8211; who&#8217;ve built market-leading products and capabilities &#8211; to scale in their domains. I&#8217;m excited about the payments team&#8217;s opportunity to transform the B2B payments experience into one that&#8217;s frictionless, reliable and one that&#8217;s set for rapid growth.&#8221;
Investors can gain exposure to the stock via&nbsp;INQQ The India Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INQQ#NYSE">INQQ</a>) and FMQQ The Next Frontier Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMQQ#NYSE">FMQQ</a>).
Price Action: MMYT shares are up 0.99% at $98.50 premarket at the last check Monday.
Image generated using DALL-E
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42033411" target="_blank" rel="noreferrer noopener">Cybersecurity Gets A Boost: BlackBerry, Canada, And TMU Team Up To Fortify ASEAN&#8217;s Digital Defenses</a></li>
</ul>

Equities

Large Cap

Travel

General

FMQQ The Next Frontier Internet & Ecommerce ETF

FMQQ

Exchange Traded Concepts Trust India Internet & Ecommerce ETF

INQQ

MakeMyTrip Agrees To Acquire Happay, Bolstering Its Arsenal For Corporate Travel Solutions

MakeMyTrip, India's leading online travel company, today announced that it has signed a Business Transfer Agreement to acquire Happay Expense Management Platform from CRED. This acquisition reinforces MakeMyTrip's commitment to becoming the go-to platform for comprehensive corporate travel and expense management solutions.
Happay is a leader in expense management, with robust capabilities in product development, data-driven insights, and scalable solutions that consistently drive value and efficiency for clients. Under the agreement, Happay brand, its expense management business, and its dedicated team will transition to MakeMyTrip.
"We have consistently outpaced industry growth in the corporate travel sector over the past few years by focusing on innovation and seamless user experience," said Rajesh Magow, Co-Founder and Group CEO, MakeMyTrip. "The acquisition of Happay's brand and expense management platform is a natural next step in our strategy to lead this space. By integrating Happay's expertise, which spans over 900 corporate clients, MakeMyTrip is set to redefine the benchmarks once again in corporate travel and expense management in India."
The transaction is expected to close within the next 90 days, subject to closing conditions. Happay's team will continue to seamlessly support the existing client base while working in close partnership with MakeMyTrip's corporate travel services team.

MakeMyTrip Takes Over Happay Expense Platform From CRED, Targets Corporate Travel Growth, Financial Terms Undiclosed

B of A Securities analyst Sachin Salgaonkar maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $112 to $119.

B of A Securities Maintains Buy on MakeMyTrip, Raises Price Target to $119

MakeMyTrip shares are trading lower. The company reported Q2 financial results.

MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.26 by 38.46 percent. This is a 44 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $230.268 million which beat the analyst consensus estimate of $215.001 million by 7.10 percent. This is a 22.02 percent increase over sales of $188.708 million the same period last year.

Earnings

Earnings Beats

MakeMyTrip Q2 2025 Adj. EPS $0.36 Beats $0.26 Estimate, Sales $230.268M Beat $215.001M Estimate

MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) is preparing to release its quarterly earnings on Wednesday, 2024-10-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect MakeMyTrip to report an earnings per share (EPS) of $0.26.
MakeMyTrip bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
Last quarter the company beat EPS by $0.11, which was followed by a 6.23% drop in the share price the next day.
Here's a look at MakeMyTrip's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.28</td>
<td>0.20</td>
<td>0.24</td>
<td>0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.39</td>
<td>0.38</td>
<td>0.35</td>
<td>0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729627380_0_0.png" alt="eps graph" />
<h3>MakeMyTrip Share Price Analysis</h3>
Shares of MakeMyTrip were trading at $104.59 as of October 21. Over the last 52-week period, shares are up 171.6%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analysts' Perspectives on MakeMyTrip</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MakeMyTrip.
Analysts have given MakeMyTrip a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $109.0, indicating a potential 4.22% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Norwegian Cruise Line, Hyatt Hotels and Hilton Grand Vacations, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Norwegian Cruise Line received a Neutral consensus from analysts, with an average 1-year price target of $24.65, implying a potential 76.43% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Hyatt Hotels, with an average 1-year price target of $160.12, suggesting a potential 53.09% upside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Hilton Grand Vacations, with an average 1-year price target of $41.83, implying a potential 60.01% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Norwegian Cruise Line, Hyatt Hotels and Hilton Grand Vacations are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MakeMyTrip</td>
<td>Buy</td>
<td>29.37%</td>
<td>$169.43M</td>
<td>1.87%</td>
</tr>
<tr>
<td>Norwegian Cruise Line</td>
<td>Neutral</td>
<td>7.57%</td>
<td>$917.74M</td>
<td>30.98%</td>
</tr>
<tr>
<td>Hyatt Hotels</td>
<td>Neutral</td>
<td>-0.12%</td>
<td>$361M</td>
<td>9.56%</td>
</tr>
<tr>
<td>Hilton Grand Vacations</td>
<td>Neutral</td>
<td>22.64%</td>
<td>$328M</td>
<td>0.10%</td>
</tr>
</tbody>
</table>

Key Takeaway:
MakeMyTrip ranks at the bottom for Revenue Growth among its peers. It is at the bottom for Gross Profit as well. MakeMyTrip is at the bottom for Return on Equity.
<h3>About MakeMyTrip</h3>
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
<h3>Financial Milestones: MakeMyTrip's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: MakeMyTrip displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 29.37%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: MakeMyTrip's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 8.26%, the company may face hurdles in effective cost management.
Return on Equity (ROE): MakeMyTrip's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.87%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): MakeMyTrip's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.24%, the company may face hurdles in achieving optimal financial returns.
Debt Management: MakeMyTrip's debt-to-equity ratio is below the industry average at 0.2, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MMYT/earnings">To track all earnings releases for MakeMyTrip visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: MakeMyTrip's Earnings Outlook

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Light &amp; Wonder Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>)</h3>
<ul>
<li>On Sept. 25, Macquarie analyst Chad Beynon maintained Light &amp; Wonder with an Outperform and lowered the price target from $122 to $117. The company's stock fell around 19% over the past month and has a <a href="https://www.benzinga.com/quote/LNW">52-week low of $67.71</a>.</li>
<li>RSI Value: 26.57</li>
<li>LNW Price Action: Shares of Light &amp; Wonder fell 0.2% to close at $87.74 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1">latest LNW news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="903" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065057/image-8.png" alt="" class="wp-image-578301" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065057/image-8.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065057/image-8-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065057/image-8-768x719.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">Makemytrip Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Aug. 27, B of A Securities analyst Sachin Salgaonkar maintained MakeMyTrip with a Buy and raised the price target from $100 to $112.. The company's stock fell around 18% over the past five days. It <a href="https://www.benzinga.com/quote/MMYT">has a 52-week low</a> of $36.81.</li>
<li>RSI Value: 29.31</li>
<li>MMYT Price Action: Shares of Makemytrip fell 5.2% to close at $86.91 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1">MMYT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="913" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065115/image-9.png" alt="" class="wp-image-578302" style="width:690px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065115/image-9.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065115/image-9-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065115/image-9-768x704.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<h3 class="wp-block-heading">Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>)</h3>
<ul>
<li>On Sept. 12, Mizuho analyst David Bellinger maintained Advance Auto Parts with a Neutral and lowered the price target from $45 to $38. The company's shares fell around 15% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/AAP">low of $37.08</a>.</li>
<li>RSI Value: 27.47</li>
<li>AAP Price Action: Shares of Advance Auto Parts fell 1.6% to close at $37.17 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1">breakout in AAP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065223/image-10.png" alt="" class="wp-image-578308" style="width:664px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065223/image-10.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065223/image-10-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03065223/image-10-768x719.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41156151/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Long Ideas

Top 3 Consumer Stocks Which Could Rescue Your Portfolio This Quarter

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares fell 14.37% last week after Citigroup downgraded the stock from <a href="https://www.benzinga.com/quote/smmt/analyst-ratings" target="_blank" rel="noreferrer noopener">Buy to Neutral</a> but raised its price target from $19 to $23.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) stock plummeted 12.46%.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) stock fell 9.37% after Jefferies downgraded the stock from Buy to Hold and <a href="https://www.benzinga.com/quote/medp/analyst-ratings" target="_blank" rel="noreferrer noopener">cut its price target from $415 to $345</a>.</li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) stock lost 8.94% last week after Leerink Partners <a href="https://www.benzinga.com/quote/regn/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded it</a> from Outperform to Market Perform and lowered its price target from $1,175 to $1,077.</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) shares dived 8.74% after the company guided <a href="https://www.benzinga.com/pressreleases/24/09/b41024786/global-payments-shares-updated-strategy-and-medium-term-outlook-at-investor-conference" target="_blank" rel="noreferrer noopener">FY25 EPS growth below estimates</a>, and multiple firms downgraded the stock and<a href="https://www.benzinga.com/quote/gpn/analyst-ratings" target="_blank" rel="noreferrer noopener"> cut their respective price targets</a>.</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) stock lost 8.39% last week. There was no company-specific news to justify the price loss.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares dipped 8.21% following a report indicating the company is being probed by the Department of Justice following an August short <a href="https://www.benzinga.com//node/41052423" target="_blank" rel="noreferrer noopener">report from</a><a href="https://www.benzinga.com//node/41052423" target="_blank" rel="noreferrer noopener"> Hindenburg Research</a>.</li>
<li>TechnipFMC plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) stock fell 6.10% amid reports suggesting Saudi Arabia may raise crude oil output.</li>
<li>First Citizens BancShares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) stock lost 6.09% last week after Wedbush analyst <a href="https://www.benzinga.com/quote/fcnca/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded the stock</a> from Outperform to Neutral and lowered the price target from $2,450 to $2,150.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) stock fell 5.93% from pressure following the DOJ&#8217;s Carahsoft investigation.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/41082440/chinese-stocks-dominate-jd-com-and-temu-parent-pdd-are-among-top-10-large-cap-gainers-last-week-se" target="_blank" rel="noreferrer noopener">Chinese Stocks Dominate &#8211; JD.com And Temu Parent PDD Are Among Top 10 Large Cap Gainers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Company

AFRM

FCNCA

KNTK

MEDP

REGN

SMCI

SMMT

Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?

<h3>Gainers</h3>
<ul>
<li>Gaotu Techedu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) stock increased by 26.6% to $3.69 during Thursday's regular session. The company's market cap stands at $956.4 million. </li>
<li>Fenbo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEBO#NASDAQ">FEBO</a>) stock increased by 26.6% to $6.14. The company's market cap stands at $67.9 million. </li>
<li>Jianzhi Education Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) stock increased by 24.2% to $1.06. The company's market cap stands at $21.3 million. </li>
<li>TAL Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) stock increased by 23.25% to $10.26. The market value of their outstanding shares is at $6.1 billion. </li>
<li>Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) shares moved upwards by 22.97% to $2.89. The market value of their outstanding shares is at $543.1 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Studio City Intl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) shares rose 21.39% to $7.66. The market value of their outstanding shares is at $1.4 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alta Global Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock fell 15.4% to $1.76 during Thursday's regular session. The market value of their outstanding shares is at $18.1 million. </li>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares decreased by 13.08% to $0.35. The company's market cap stands at $1.1 million. </li>
<li>Golden Sun Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSUN#NASDAQ">GSUN</a>) shares fell 11.43% to $6.2. The market value of their outstanding shares is at $12.2 million. </li>
<li>Genius Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares fell 9.78% to $0.95. The company's market cap stands at $20.5 million. </li>
<li>MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) shares fell 9.22% to $96.99. The market value of their outstanding shares is at $10.6 billion. </li>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) stock fell 8.23% to $0.48. The market value of their outstanding shares is at $33.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIEV

DBGI

FEBO

GSX Techedu Inc. American Depositary Shares

GOTU

GSUN

UXIN

12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session

Analysts' ratings for MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $105.5, a high estimate of $115.00, and a low estimate of $95.00. Witnessing a positive shift, the current average has risen by 12.23% from the previous average price target of $94.00.
<img src="https://www.benzinga.com/files/images/story/2024/1724760018_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of MakeMyTrip by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sachin Salgaonkar</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Vijit Jain</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Sachin Salgaonkar</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Sachin Salgaonkar</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MakeMyTrip. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MakeMyTrip compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for MakeMyTrip's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MakeMyTrip's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MMYT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MakeMyTrip analyst ratings.</a>
<h2>Unveiling the Story Behind MakeMyTrip</h2>
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
<h3>Financial Milestones: MakeMyTrip's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: MakeMyTrip displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 29.37%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: MakeMyTrip's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 8.26%, the company may face hurdles in effective cost management.
Return on Equity (ROE): MakeMyTrip's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.87%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.24%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying MakeMyTrip: Insights From 4 Analyst Reviews

B of A Securities analyst Sachin Salgaonkar maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $100 to $112.

B of A Securities Maintains Buy on MakeMyTrip, Raises Price Target to $112

MakeMyTrip's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NYSE">MMYT</a>) short percent of float has fallen 28.07% since its last report. The company recently reported that it has 2.67 million shares sold short, which is 4.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>MakeMyTrip Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721923218_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MakeMyTrip has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing MakeMyTrip's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MakeMyTrip's peer group average for short interest as a percentage of float is 7.38%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into MakeMyTrip's Recent Short Interest

Citigroup analyst Vijit Jain maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $93 to $115.

Citigroup Maintains Buy on MakeMyTrip, Raises Price Target to $115

B of A Securities analyst Sachin Salgaonkar maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $95 to $100.

B of A Securities Maintains Buy on MakeMyTrip, Raises Price Target to $100

Shares of Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) fell sharply during Tuesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39908857/comcasts-q2-earnings-studios-and-theme-parks-pull-revenue-lower-broadband-and-video-subs-fall">second-quarter sales results</a>.
Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Comcast shares declined 6.1% to $37.12 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 148% to $2.6299 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.</li>
<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) gained 111% to $3.2540.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares climbed 67% to $0.2390.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) rose 45% to $2.7950.</li>
<li>Dermata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) gained 43% to $2.41.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 36.5% to $4.60.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) gained 33.5% to $0.6385 after jumping around 20% on Monday.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares climbed 30% to $13.11 following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
<li>Mammoth Energy Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TUSK#NASDAQ">TUSK</a>) gained 26% to $4.42 after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.</li>
<li>iClick Interactive Asia Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>) rose 23.5% to $2.05.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) jumped 19.3% to $2.90.</li>
<li>Milestone Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#NYSE">MLSS</a>) gained 17.5% to $1.02 after the company announced the Medicare price assignment for its CompuFlo Epidural System.</li>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) gained 16% to $2.1493.</li>
<li>Kiniksa Pharmaceuticals International, plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) rose 16% to $24.81 after the company reported better-than-expected second-quarter sales results and raised its FY24 net product revenue guidance.</li>
<li>Aeva Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) gained 15.1% to $3.6713.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) jumped 12.7% to $333.02 following second-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) gained 11.8% to $12.34.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) rose 11.8% to $6.90.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) gained 11.1% to $561.96 following better-than-expected second-quarter financial results.</li>
<li>Crown Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) rose 8.5% to $84.04 after the company reported better-than-expected second-quarter earnings and raised its FY24 EPS guidance above estimates.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) gained 8% to $96.75 following better-than-expected quarterly earnings.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) gained 8% to $16.51 as the company released preliminary second quarter 2024 financial results and signed a definitive agreement to acquire Rotech Healthcare for $1.36 billion in cash.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares surged 8% to $8.15. Mesoblast recently started enrollment in Phase 3 trial of Rexlemestrocel-L for chronic low back pain.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) climbed 7.7% to $86.19 after the company reported better-than-expected second quarter financial results and revised its FY24 adjusted EPS guidance above estimates.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) gained 7.4% to $269.35 after the company reported better-than-expected second quarter earnings.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) gained 6.4% to $173.21 after the company reported better-than-expected second quarter adjusted EPS and raised its FY24 outlook.</li>
<li>SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) rose 6% to $0.2390 after the company reported second-quarter financial results.</li>
<li>Zions Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) gained 5.4% to $52.12 after posting better-than-expected quarterly results on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares dipped 65% to $1.50 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.</li>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) dipped 62.2% to $0.2999 after the company announced a proposed public offering.</li>
<li>Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) tumbled 59.2% to $2.60.</li>
<li>MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares dipped 50.3% to $2.4636. MIRA Pharmaceuticals shares jumped 627% on Monday after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 38.3% to $3.1851 after surging 228% on Monday.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) dipped 32.4% to $0.0250.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) fell 32.2% to $1.83.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) fell 31.1% to $0.3440.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) dipped 26.2% to $2.23. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) fell 23% to $0.77.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) fell 20% to $0.1594. Castellum recently announced a new strategic alliance with Krilla Kaleiwahea.</li>
<li>Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) fell 17.3% to $0.0926 after gaining around 8% on Monday.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares declined 16.6% to $364.00 after the company reported mixed second-quarter financial results and narrowed its FY24 revenue guidance with its midpoint below estimates.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) dipped 15.2% to $16.48.</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) fell 13.2% to $126.04 after the company reported worse-than-expected quarterly financial results.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) shares fell 10% to $0.4479 after gaining over 55% on Monday.</li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) shares fell 9.5% to $256.55 following mixed second-quarter earnings.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) dipped 9.2% to $23.28.</li>
<li>PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) fell 8.4% to $99.92 after the company reported worse-than-expected second-quarter financial results.</li>
<li>A. O. Smith Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) declined 8.4% to $81.30. The company reported second-quarter financial results.</li>
<li>WEBTOON Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) dipped 7.7% to $22.00.</li>
<li>Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) declined 7.2% to $76.23 after the company reported worse-than-expected second-quarter financial results and cut its guidance.</li>
<li>Archrock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) shares declined 6.9% to $21.76. Archrock commenced public offering of 11 million shares of its common stock and announced plans to acquire Total Operations and Production Services for $983 million in cash and stock.</li>
<li>General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) fell 6.1% to $46.52 after the company reported second-quarter financial results. Also, the company announced that it delayed its 2024 Buick EV and pushed its EV pickup plant opening to 2026.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39907957/microsoft-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday">Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

ADIL

AEVA

AROC

ATPC

AZTR

CGBS

CLRB

CMAX

CMCSA

DRMA

EFSH

FEIM

FLYE

FTEL

ICLK

JAGX

KNSA

MESO

MIRA

MLSS

MSCI

NCPL

NUKK

NXPI

PCAR

PSIG

RNAZ

SLNA

SLRX

SMFL

SOAR

SPOT

STAF

TUSK

WBTN

XCUR

ZION

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gaurav Rateria, an analyst from Morgan Stanley, maintained the Buy rating on Makemytrip (MMYT – Research Report). The associated price target remai...

MakeMyTrip: Strong Market Positioning and Financial Health Drive Buy Recommendation

MakeMyTrip (MMYT) announced that it has signed a business transfer agreement to acquire Happay Expense Management Platform from CRED. This acquisit...

MakeMyTrip to acquire Happay Expense Management Platform, terms undisclosed

MakeMyTrip to acquire Happay Expense Management Platform from CRED

Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Macy's (M – Research Report), Blue Bird (BL...

Analysts Offer Insights on Consumer Cyclical Companies: Macy's (M), Blue Bird (BLBD) and Makemytrip (MMYT)

Invesco EQV Emerging Markets All Cap Fund Q3 2024 Commentary

Around The World In 80 Stocks: A Global Hunt For Value

BofA analyst Sachin Salgaonkar raised the firm's price target on MakeMyTrip (MMYT) to $130 from $119 and keeps a Buy rating on the shares. The firm...

MakeMyTrip price target raised to $130 from $119 at BofA

Top ranked Indian equities according to SA Quant

Artisan Developing World Fund Q4 2024 Commentary

Catalyst Watch: Netflix earnings, Monster Beverage event, drug data, and quantum volatility

Comments

MakeMyTrip

空売り

MakeMyTrip (NASDAQ:MMYT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル